Welcome to AZNeuro

Partnering with the best to advance AstraZeneca’s Neuroscience pipeline

Welcome to the AZNeuro IMED

As part of AstraZeneca’s long term commitment to patients with a wide range of degenerative and other neurological and psychiatric diseases, our small, nimble, biotech-like Neuroscience group is responding to breaking science by rapidly capitalising on new opportunities, aiming to deliver a portfolio of first and best-in-class medicines.

Based predominantly in Cambridge, UK, with a smaller footprint in the US, our neuroscience organisation is progressing our unique portfolio of small molecule and biologic therapies, exploiting breaking science in new modalities, such as proteolysis targeting chimeras (PROTACs) and antibody-drug conjugates, and utilising artificial intelligence (AI) and machine learning to identify the best molecules to meet the exacting demands of central nervous system (CNS) therapeutics.

As a small, focussed and agile group, we respond to new discoveries as they happen. Following observations that many neurodegenerative diseases have a common mechanism in which pathological proteins spread from neurone to neurone, we have invested in projects targeting alpha (ɑ)-synuclein and tau, proteins involved in Parkinson’s disease and Alzheimer’s disease, respectively, and brought forward development of molecules such as MEDI1341 (ɑ-synuclein antibody).

We are excited to report that we have entered a partnership with Takeda to work jointly on MEDI1341 for Parkinson’s disease. We have continued our ongoing collaboration with Eli Lilly and Company with MEDI1814, an amyloid-beta 42 (Aβ42) selective antibody which targets pathological proteins in Alzheimer’s disease. This complements our collaboration on AZD3293, our oral, potent, small molecule beta secretase (BACE) inhibitor.

We have documented our scientific progress and findings in a number of high impact and high quality scientific papers.

Our consistent commitment to high quality science has led to a strong portfolio with the potential to provide the next wave of revenue generation for AstraZeneca, and positively affect the lives of those living with neurodegenerative diseases, chronic pain, or psychiatric conditions.